公开(公告)号：US20220177585A1

公开(公告)日：2022-06-09

申请号：US17349482

申请日：2021-06-16

Applicant: GENMAB A/S

Inventor： Catharina Emanuele GERARDA HAVENITH ,  Tom VINK ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/28 ,  G01N33/566

Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

公开(公告)号：US20220169738A1

公开(公告)日：2022-06-02

申请号：US17369542

申请日：2021-07-07

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20220033510A1

公开(公告)日：2022-02-03

申请号：US17360438

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20210369842A1

公开(公告)日：2021-12-02

申请号：US17289602

申请日：2019-11-06

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61K47/22 ,  A61K47/26 ,  A61K9/00

Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.

公开(公告)号：US11180572B2

公开(公告)日：2021-11-23

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  C07K16/32 ,  C07K16/10 ,  C07K16/36 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20210355232A1

公开(公告)日：2021-11-18

申请号：US17382758

申请日：2021-07-22

Applicant: GENMAB HOLDING B.V.

Inventor： Simone OOSTINDIE ,  Frank BEURSKENS ,  Esther BREIJ ,  Edward VAN DEN BRINK ,  Andreas HOLLENSTEIN ,  Marije OVERDIJK ,  Margaret LINDORFER ,  Ronald TAYLOR ,  Paul PARREN ,  Hilma VAN DER HORST ,  Martine E.D. CHAMULEAU ,  Tuna MUTIS

IPC: C07K16/28 ,  A61P35/00 ,  A61K49/00 ,  G01N33/68

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

公开(公告)号：US20210308208A1

公开(公告)日：2021-10-07

申请号：US17268387

申请日：2019-08-14

Applicant: Genmab A/S

Inventor： Reshma A. RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Bart DE GOEIJ ,  Oyewale O. ABIDOYE ,  Leonardo V. NICACIO ,  Stephen C. ALLEY

IPC: A61K38/07 ,  A61K47/68 ,  A61K47/65 ,  A61K47/54 ,  A61P35/00

Abstract: The invention provides methods and compositions for treating cancer, such as ovarian cancer, peritoneal cancer, and fallopian tube cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., ovarian cancer, peritoneal cancer, and fallopian tube cancer).

公开(公告)号：US11046771B2

公开(公告)日：2021-06-29

申请号：US15832366

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20210122830A1

公开(公告)日：2021-04-29

申请号：US17003442

申请日：2020-08-26

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Edward N. VAN DEN BRINK ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD, D.M.Sc. ,  David SATIJN ,  Jan VAN DE WINKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20210107985A1

公开(公告)日：2021-04-15

申请号：US16883333

申请日：2020-05-26

Applicant: GENMAB A/S

Inventor： Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G. J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06 ,  C07K16/42 ,  C07K16/46 ,  G01N33/574 ,  G01N33/569

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.